Help of historically highest value of approximately 9.4 billion is available in the newly opened tenth challenge 2 IMI (Innovative Medicines Initiative 2), which is focused on research for new drugs and issues related to the sharing of medical data across Europe.
The support may apply consortium assembled for this purpose, representatives of small and medium-sized companies, academic institutions (ie. The research team backed by any university or institution) and “guarantors” of large pharmaceutical industry, who provide the necessary data and share their know-how. Consortia must always be international.
For more info, click here.